Importance of ABCC1 for cancer therapy and prognosis

Drug Metabolism Reviews

Volumn 46, Issue 3, 2014, Pages 325-342

  Kunická, Tereza ^a,b   Souček, Pavel ^a,b  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Drug; Expression; Polymorphism; Prediction; Resistance

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; XENOBIOTIC AGENT;

BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; CARCINOMA; COLORECTAL CARCINOMA; DRUG TREATMENT FAILURE; ENZYME SPECIFICITY; GENE; GENETIC VARIABILITY; HUMAN; KIDNEY CARCINOMA; LUNG CARCINOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANCE; MULTIDRUG RESISTANCE ASSOCIATED GENE 1; NEUROBLASTOMA; NONHUMAN; OVARY CARCINOMA; PANCREAS CARCINOMA; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; TISSUE DISTRIBUTION; TREATMENT OUTCOME; ANIMAL; DRUG RESISTANCE; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; PROGNOSIS;

ANIMALS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS; PROGNOSIS; XENOBIOTICS;

EID: 84905493763     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2014.901348     Document Type: Review

References (265)

1. Abbott BL. (2003). ABCG2 (BCRP) Expression in normal and malignant hematopoietic cells. Hematol Oncol 21:115-130.
2. Akan I, Akan S, Akca H, et al. (2005). Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: Effects of N-acetylcysteine and Buthionine sulfoximine. Cancer Cell Int 5:22.
3. Alexander D, Yamamoto T, Kato S, Kasai S. (1999). Histopathological assessment of multidrug resistance in gastric cancer: Expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein. Surg Today 29:401-406.
4. Ambudkar SV, Dey S, Hrycyna CA, et al. (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
5. Ambudkar SV, Kim IW, Xia D, Sauna ZE. (2006). The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding. FEBS Lett 580: 1049-1055.
6. Anderle P, Sengstag T, Mutch DM, et al. (2005). Changes in the transcriptional profile of transporters in the intestine along the anterior-posterior and crypt-villus axes. BMC Genomics 6:69.
7. Annilo T, Dean M. (2004). Degeneration of an ATP-binding cassette transporter gene, ABCC13, in different mammalian lineages. Genomics 84:34-46.
8. Arienti C, Tesei A, Verdecchia GM, et al. (2013). Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. Clin Colorectal Cancer 12:122-127.
9. Auner V, Sehouli J, Oskay-Oezcelik G, et al. (2010). ABC transporter gene expression in benign and malignant ovarian tissue. Gynecol Oncol 117:198-201.
10. Bader P, Schilling F, Schlaud M, et al. (1999). Expression analysis of multidrug resistance associated genes in neuroblastomas. Oncol Rep 6:1143-1146.
11. Bakos E, Hegedus T, Hollo Z, et al. (1996). Membrane topology and glycosylation of the human multidrug resistance-associated protein. J Biol Chem 271:12322-12326.
12. Bakos E, Homolya L. (2007). Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch 453:621-641.
13. Bakos E, Evers R, Sinkó E, et al. (2000). Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 57:760-768.
14. Balatzenko G, Stoimenov A, Guenova M, et al. (2002). Application of reverse transcription polymerase chain reaction for analysis of multidrug resistance in patients with acute myeloblastic leukemia. J BUON 7:355-359.
15. Barnouin K, Leier I, Jedlitschky G, et al. (1998). Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Br J Cancer 77:201-209.
16. Bart J, Hollema H, Groen HJ, et al. (2004). The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer 40: 2064-2070.
17. Berger W, Elbling L, Hauptmann E, Micksche M. (1997). Expression of the multidrug resistance-associated protein (MRP) and chemoresis-tance of human non-small-cell lung cancer cells. Int J Cancer 73: 84-93.
18. Berger W, Setinek U, Hollaus P, et al. (2005). Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: Prognostic implications. J Cancer Res Clin Oncol 131:355-363.
19. Biedler JL, Riehm H. (1970). Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 30:1174-1184.
20. Bordow SB, Haber M, Madafiglio J, et al. (1994). Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplificationand overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 54:5036-5040.
21. Borel F, Han R, Visser A, et al. (2012). Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 55: 821-832.
22. Borst P, Evers R, Kool M, Wijnholds J. (1999). The multidrug resistance protein family. Biochim Biophys Acta 1461:347-357.
23. Boumendjel A, Baubichon-Cortay H, Trompier D, et al. (2005). Anticancer multidrug resistence mediated by MRP1: Recent advances in the discovery of reversal agents. Med Res Rev 25:453-472.
24. Brandmann M, Tulpule K, Schmidt MM, Dringen R. (2012). The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes. J Neurochem 120:78-92.
25. Brodeur GM. (2003). Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 3:203-216.
26. Broyl A, Corthals SL, Jongen JL, et al. (2010). Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: A prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 11: 1057-1065.
27. Bryan J, Munoz A, Zhang X, et al. (2007). ABCC8 and ABCC9: ABC transporters that regulate K+ channels. Pflugers Arch 453:703-718.
28. Burkhart CA, Cheng AJ, Madafiglio J, et al. (2003). Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst 95:1394-1403.
29. Cecchin E, D'Andrea M, Lonardi S, et al. (2013). A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J 13:403-409.
30. Chan HS, Lu Y, Grogan TM, et al. (1997). Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res 57:2325-2330.
31. Chauhan PS, Bhushan B, Singh LC, et al. (2012). Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: Response to induction chemotherapy. Exp Mol Pathol 92:44-49.
32. Chen ZS, Furukawa T, Sumizawa T, et al. (1999). ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 55:921-928.
33. Choudhuri S, Klassen CD. (2006). Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25:231-259.
34. Cole SP. (2014). Targeting multidrug resistance protein 1 (MRP1, ABCC1): Past, present, and future. Annu Rev Pharmacol Toxicol 54: 95-117.
35. Cole SP, Bhardwaj G, Gerlach JH, et al. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654.
36. Cole SP, Sparks KE, Fraser K, et al. (1994). Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902-5910.
37. Colombo S, Soranzo N, Rotger M, et al. (2005). Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics 15:599-608.
38. Conrad S, Kauffmann HM, Ito K, et al. (2001). Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J Hum Genet 46:656-663.
39. Conrad S, Kauffmann HM, Ito K, et al. (2002). A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12:321-330.
40. Conseil G, Cole SP. (2013). Two polymorphic variants of ABCC1 selectively alter drug resistance and inhibitor sensitivity of the multidrug and organic anion transporter multidrug resistance protein 1. Drug Metab Dispos 41:2187-2196.
41. Conseil G, Deeley RG, Cole SP. (2005). Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet Genomics 15:523-533.
42. Cutler MJ, Urquhart BL, Velenosi TJ, et al. (2012). In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol 52:530-542.
43. Dallas S, Zhu X, Baruchel S, et al. (2003). Functional expression of the multidrug resistance protein 1 in microglia. J Pharmacol Exp Ther 307:282-290.
44. Dean M, Rzhetsky A, Allikmets R. (2001). The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11:1156-1166.
45. Deeley RG, Westlake C, Cole SP. (2006). Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86:849-899.
46. Diestra JE, Condom E, Del Muro XG, et al. (2003). Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: Biological and clinical implications. J Urol 170: 1383-1387.
47. Duffy CP, Elliott CJ, O'Connor RA, et al. (1998). Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 34:1250-1259.
48. Ehrlichova M, Mohelnikova-Duchonova B, Hrdy J, et al. (2013). The association of taxane resistance genes with the clinical course of ovarian carcinoma. Genomics 102:96-101.
49. El Azreq MA, Naci D, Aoudjit F. (2012). Collagen/b1 integrin signaling up-regulates the ABCC1/MRP-1 transporter in an ERK/MAPK-dependent manner. Mol Biol Cell 23:3473-3484.
50. El-Readi MZ, Eid S, Ashour ML, et al. (2013). Modulation of multidrug resistancein cancer cells by chelidonine and Chelidonium majus alkaloids. Phytomedicine 20:282-294.
51. Elsby R, Smith V, Fox L, et al. (2011). Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica 41: 764-783.
52. Endo K, Maehara Y, Ichiyoshi Y, et al. (1996). Multidrug resistance-associated protein expression in clinical gastric carcinoma. Cancer 77: 1681-1687.
53. Evers R, Zaman GJ, van Deemter L, et al. (1996). Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 97: 1211-1218.
54. Faggad A, Darb-Esfahani S, Wirtz R, et al. (2009). Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: Implication for prognosis. Histopathology 54:657-666.
55. Ferguson LR, De Flora S. (2005). Multiple drug resistance, antimuta-genesis and anticarcinogenesis. Mutat Res 591:24-33.
56. Ferlay J, Parkin DM, Steliarova-Foucher E. (2010). Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781.
57. Filipits M, Haddad V, Schmid K, et al. (2007). Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 13: 3892-3898.
58. Filipits M, Malayeri R, Suchomel RW, et al. (1999). Expression of the multidrug resistance protein (MRP1) in breast cancer. Anticancer Res 19:5043-5049.
59. Filipits M, Pohl G, Rudas M, et al. (2005). Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: The Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 23:1161-1168.
60. Filipits M, Suchomel RW, Dekan G, et al. (1996). MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 2: 1231-1237.
61. Flens MJ, Zaman GJ, van der Valk P, et al. (1996). Tissue distribution of the multidrug resistance protein. Am J Pathol 148:1237-1247.
62. Foster NR, Mandrekar SJ, Schild SE, et al. (2009). Prognostic factors differ by tumor stage for small cell lung cancer: A pooled analysis of North Central Cancer Treatment Group trials. Cancer 115:2721-2731.
63. Fukushima Y, Oshika Y, Tokunaga T, et al. (1999). Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer. Eur J Cancer 35:935-938.
64. Gandhi L, Harding MW, Neubauer M, et al. (2007). A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer 109:924-932.
65. Gao M, Cui HR, Loe DW, et al. (2000). Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1. J Biol Chem 275:13098-13108.
66. Ge J, Chen Z, Wu S, et al. (2009). Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion 80:148-158.
67. Gennuso F, Fernetti C, Tirolo C, et al. (2004). Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). Proc Natl Acad Sci USA 101:2470-2475.
68. Germann UA, Shlyakhter D, Mason VS, et al. (1997). Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8:125-140.
69. Goldhirsch A, Colleoni M, Domenighetti G, Gelber RD. (2003). Systemic treatments for women with breast cancer: Outcome with relation to screening for the disease. Ann Oncol 14:1212-1214.
70. Goldman B. (2003). Multidrug resistance: Can new drugs help chemotherapy score against cancer? J Natl Cancer Inst 95:255-257.
71. Gomez A, Ingelman-Sundberg M. (2009). Pharmacoepigenetics: Its role in interindividual differences in drug response. Clin Pharmacol Ther 85:426-430.
72. Gottesman MM, Fojo T, Bates SE. (2002). Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48-58.
73. Gottesman MM, Pastan I, Ambudkar SV. (1996). P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6:610-617.
74. Grant CE, Kurz EU, Cole SP, Deeley RG. (1997). Analysis of the intron-exon organization of the human multidrug-resistance protein gene (MRP) and alternative splicing of its mRNA. Genomics 45:368-378.
75. Greaves W, Xiao L, Sanchez-Espiridion B, et al. (2012). Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. J Hematol Oncol 5:47. doi:10.1186/1756-8722-5-47.
76. Gromicho M, Dinis J, Magalhaes M, et al. (2011). Development of imatinib and dasatinib resistance: Dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk Lymphoma 52:1980-1990.
77. Grzywacz MJ, Yang JM, Hait WN. (2003). Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide. Cancer Res 63:2492-2498.
78. Gu L, Findley HW, Zhou M. (2002). MDM2 induces NF-kappaB/p65 expression transcriptionally through Sp1-binding sites: A novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood 99:3367-3375.
79. Gutmann H, Török M, Fricker G, et al. (1999). Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro. Drug Metab Dispos 27:937-941.
80. Haber M, Bordow S, Gilbert J, et al. (1999). Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells. Oncogene 18:2777-2782.
81. Haber M, Smith J, Bordow SB, et al. (2006). Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 24:1546-1553.
82. Hait WN, Yang JM. (2006). The individualization of cancer therapy: The unexpected role of p53. Trans Am Clin Climatol Assoc 117:85-101.
83. Hayashi A, Suzuki H, Itoh K, et al. (2003). Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochem Biophys Res Commun 310:824-829.
84. Henderson MJ, Haber M, Porro A, et al. (2011). ABCC multidrug transporters in childhood neuroblastoma: Clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst 103: 1236-1251.
85. Hennessy BT, Coleman RL, Markman M. (2009). Ovarian cancer. Lancet 374:1371-1382.
86. Hermann DM, Kilic E, Spudich A, et al. (2006). Role of drug efflux carriers in the healthy and diseased brain. Ann Neurol 60: 489-498.
87. Hidaka H, Seki N, Yoshino H, et al. (2012). Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma. Oncotarget 3: 44-57.
88. Higgins CF. (1992). ABC transporters: From microoganisms to man. Annu Rev Cell Biol 8:67-113.
89. Hinoshita E, Uchiumi T, Taguchi K, et al. (2000). Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 6: 2401-2407.
90. Hipfner DR, Deeley RG, Cole SP. (1999). Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1461:359-376.
91. Hipfner DR, Gauldie SD, Deeley RG, Cole SP. (1994). Detection of the M(r) 190, 000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 54:5788-5792.
92. Hlavác V, Brynychová V, Václav́iková R, et al. (2013) The expression profile of ABC transporter genes in breast carcinoma. Pharmacogenomics 14: 515-529.
93. Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, et al. (2012). The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis 27:187-196.
94. Hodorová I, Rybárová S, Solár P, et al. (2008). Multidrug resistance proteins in renal cell carcinoma. Folia Biol (Praha) 54:187-192.
95. Hoffmann K, Shibo L, Xiao Z, et al. (2011). Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma. Anticancer Res 31:3883-3890.
96. Hoogeveen AT, Keulemans J, Willemsen R, et al. (1991). Immunological localization of cystic fibrosis candidate gene products. Exp Cell Res 193:435-437.
97. Horiguchi S, Shiraha H, Nagahara T, et al. (2013). Loss of runt-related transcription factor 3 induces gemcitabine resistance in pancreatic cancer. Mol Oncol 7:840-849.
98. Hsia TC, Lin CC, Wang JJ, et al. (2002). Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. Lung 180: 173-179.
99. Husain AN. (2013). Lung. In: Kumar V, Abbas AK, Aster JC, eds. Robbins Basic Pathology. 9th ed. Philadelphia (PA): Elsevier/Saunders, 459-517.
100. Hyde SC, Emsley P, Hartshorn MJ, et al. (1990). Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346:362-365.
101. Innocenti F, Kroetz DL, Schuetz E, et al. (2009). Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmaco-kinetics. J Clin Oncol 27:2604-2614.
102. Iram SH, Cole SP. (2011). Expression and function of human MRP1 (ABCC1) is dependent on amino acids in cytoplasmic loop 5 and its interface with nucleotide binding domain 2. J Biol Chem 286: 7202-7213.
103. Ito S, Ieiri I, Tanabe M, et al. (2001). Polymorphisms of the ABC transporter genes, NDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11:175-184.
104. Jedlitschky G, Tirschmann K, Lubenow LE, et al. (2004). The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood 104:3603-3610.
105. Jeha S. (2003). Who should be treating adolescents and young adults with acute lymphoblastic leukaemia? Eur J Cancer 39:2579-2583.
106. Jemal A, Siegel R, Xu J, Ward E. (2010). Cancer statistics, 2010. CA Cancer J Clin 60:277-300.
107. Jungsuwadee P, Zhao T, Stolarczyk EI, et al. (2012). The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenal. Pharmacogenet Genomics 22:273-284.
108. Juszczynski P, Niewiarowski W, Krykowski E, et al. (2002). Expression of the multidrug resistanceassociated protein (mrp) gene in chronic lymphocytic leukemia. Leuk Lymphoma 43:153-158.
109. Kamazawa S, Kigawa J, Kanamori Y, et al. (2002). Multidrug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 86:171-176.
110. Kao A, Shiun SC, Hsu NY, et al. (2001). Technetium-99m methox-yisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression. Ann Oncol 12:1561-1566.
111. Kartenbeck J, Leuschner U, Mayer R, Keppler D. (1996). Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 23: 1061-1066.
112. Kato S, Ito K, Kato Y, et al. (2009). Involvement of multidrug resistance-associated protein 1 in intestinal toxicity of methotrexate. Pharm Res 26:1467-1476.
113. Kigawa J, Minagawa Y, Cheng X, Terakawa N. (1998). Gamma-glutamyl cystein synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer. Clin Cancer Res 4:1737-1741.
114. Kilic E, Spudich A, Kilic U, et al. (2008). ABCC1: A gateway for pharmacological compounds to the ischaemic brain. Brain 131: 2679-2689.
115. Kim H, Kim K, No JH, et al. (2012). Prognostic value of biomarkers related to drug resistance in patients with advanced epithelial ovarian cancer. Anticancer Res 32:589-594.
116. Kim WJ, Kakehi Y, Kinoshita H, et al. (1996). Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP), glutathione-Stransferase-pi (GST-pi) and DNA topoisomer-ase II (Topo II) genes in renal cell carcinomas and normal kidney. J Urol 156:506-511.
117. Kim YH, Ishii G, Goto K, et al. (2009). Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 65:105-111.
118. König J, Hartel M, Nies AT, et al. (2005). Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer 115:359-367.
119. Ku JL, Shin YK, Kim DW, et al. (2010). Establishment and characterization of 13 human colorectal carcinoma cell lines: Mutations of genes and expressions of drug-sensitivity genes and cancer stem cell markers. Carcinogenesis 31:1003-1009.
120. Kurz EU, Cole SP, Deeley RG. (2001). Identification of DNA-protein interactions in the 5 flanking and 5 untranslated regions of the human multidrug resistance protein (MRP1) gene: Evaluation of a putative antioxidant response element/AP-1 binding site. Biochem Biophys Res Commun 285:981-990.
121. Lacueva J, Perez-Ramos M, Soto JL, et al. (2005). Multidrug resistance-associated protein (MRP1) gene is strongly expressed in gastric carcinomas. Analysis by immunohistochemistry and real-time quantitative RT-PCR. Histopathology 46:389-395.
122. Langer R, Ott K, Feith M, et al. (2010). High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J Surg Oncol 102:503-508.
123. Langer R, Specht K, Becker K, et al. (2005). Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 11:7462-7469.
124. Larkin A, O'Driscoll L, Kennedy S, et al. (2004). Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: A prognostic study. Int J Cancer 112:286-294.
125. Lee JH, Um JW, Lee JH. (2012). Can immunohistochemistry of multidrug-resistant proteins replace the histoculture drug response assay in colorectal adenocarcinomas? Hepatogastroenterology 59: 1075-1078.
126. Leier I, Jedlitschky G, Buchholz U, et al. (1994). The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 269:27807-27810.
127. Leonessa F, Clarke R. (2003). ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43-73.
128. Leschziner G, Zabaneh D, Pirmohamed M, et al. (2006). Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenet Genomics 16: 439-450.
129. Leslie EM, Deeley RG, Cole SP. (2005). Multidrug resistance proteins: Role of P-glykoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237.
130. Leslie EM, Deeley RG, Cole SP. (2001a). Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167:3-23.
131. Leslie EM, Mao Q, Oleschuk CJ, et al. (2001b). Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol Pharmacol 59:1171-1180.
132. Leslie EM, Létourneau IJ, Deeley RG, Cole SP. (2003). Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry 42:5214-5224.
133. Letourneau IJ, Deeley RG, Cole SP. (2005). Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet Genomics 15:647-657.
134. Li H, Zhou S, Li T, et al. (2012). Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference. Hepatogastroenterology 59:2238-2242.
135. Li J, Li ZN, Yu LC, et al. (2010). Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer 69:116-122.
136. Li J, Li ZN, Du YJ, et al. (2009). Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: Correlation with response to chemotherapy and survival. Clin Lung Cancer 10: 414-421.
137. Liang Z, Wu H, Xia J, et al. (2010). Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 79:817-824.
138. Ling V. (1997). Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40:S3-S8.
139. Liscovitch M, Lavie Y. (2002). Cancer multidrug resistance: A review of recent drug discovery research. IDrugs 5:349-355.
140. Loe DW, Almquist KC, Deeley RG, Cole SP. (1996). Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 271: 9675-9682.
141. Loe DW, Stewart RK, Massey TE, et al. (1997). ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol Pharmacol 51: 1034-1041.
142. Loe DW, Deeley RG, Cole SP (2000). Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). J Pharmacol Exp Ther 293:530-538.
143. Loscher W, Potschka H. (2005). Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2:86-98.
144. Lv H, He Z, Liu X, et al. (2007). Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs. J Cell Biochem 102:75-81.
145. Maliepaard M, Scheffer GL, Faneyte IF, et al. (2001). Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
146. Manohar CF, Bray JA, Salwen HR, et al. (2004). MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. Oncogene 23:753-762.
147. Marsh S, Paul J, King CR, et al. (2007). Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 25:4528-4535.
148. Mbuna J, Kaneta T, Imasaka T. (2011). Rapid determination of multidrug resistance-associated protein in cancer cells by capillary electrophoresis immunoassay. J Chromatogr A 1218: 3923-3927.
149. Merk J, Rolff J, Dorn C, et al. (2011). Chemoresistance in non-small-cell lung cancer: Can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? Eur J Cardiothorac Surg 40:e29-e33.
150. Michaelis M, Rothweiler F, Klassert D, et al. (2009). Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res 69:416-421.
151. Minderman H, O'Loughlin KL, Pendyala L, Baer MR. (2004). VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 10: 1826-1834.
152. Mody R, Li S, Dover DC, et al. (2008). Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Blood 111: 5515-5523.
153. Mohelnikova-Duchonova B, Brynychova V, Oliverius M, et al. (2013). Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and non-neoplastic tissues. Pancreas 42: 707-716.
154. Moitra K, Lou H, Dean M. (2011). Multidrug efflux pumps and cancer stem cells: Insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 89:491-502.
155. Morrow CS, Peklak-Scott C, Bishwokarma B, et al. (2006). Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol 69:1499-1505.
156. Mueller S, Matthay KK. (2009). Neuroblastoma: Biology and staging. Curr Oncol Rep 11:431-438.
157. Muller M, Yong M, Peng XH, et al. (2001). Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1). Biochemistry 41:10123-10132.
158. Mulrooney DA, Yeazel MW, Kawashima T, et al. (2009). Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606.
159. Myette RL, Conseil G, Ebert SP, et al. (2013). Chalcogenopyrylium dyes as differential modulators of organic anion transport by multidrug resistance protein 1 (MRP1), MRP2, and MRP4. Drug Metab Dispos 41:1231-1239
160. National Comprehensive Cancer Network. (2010). NCCN clinical practice guidelines in oncology™. Breast Cancer V.2.2010. Available from: http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf [last accessed 24 May 2010].
161. Nooter K, de la Riviere GB, Klijn J, et al. (1997a). Multidrug resistance protein in recurrent breast cancer. Lancet 349:1885-1886.
162. Nooter K, de la Riviere GB, Look MP, et al. (1997b). The prognostic significance of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 76:486-493.
163. Norris MD, Bordow SB, Marshall GM, et al. (1996). Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334:231-238.
164. O'Connor R. (2007). The pharmacology of cancer resistance. Anticancer Res 27:1267-1272.
165. O'Connor R, Heenan M, Connolly L, et al. (2004). Increased anti.tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res 24: 457-464.
166. O'Connor R, O'Leary M, Ballot J, et al. (2007). A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharamacol 59:79-87.
167. Obata H, Yahata T, Quan J, et al. (2006). Association between single nucleotide polymorphisms of drug resistance-associated genes and response to
168. O'Driscoll L, Walsh N, Larkin A, et al. (2007). MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma. Anticancer Res 27:2115-2120.
169. Ohishi Y, Oda Y, Uchiumi T, et al. (2002). ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res 8:3767-3775.
170. Ohtsuki S, Kamoi M, Watanabe Y, et al. (2007). Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor. Biol Pharm Bull 30:1144-1146.
171. Oselin K, Mrozikiewicz PM, Gaikovitch E, et al. (2003). Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: Detection of a novel mutation G816A in the human MRP1 gene. Eur J Clin Pharmacol 59:347-350.
172. Ostrow JD, Pascolo L, Brites D, Tiribelli C. (2004). Molecular basis of bilirubin-induced neurotoxicity. Trends Mol Med 10:65-70.
173. Oudard S, Banu E, Beuzeboc P, et al. (2005). Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23: 3343-3351.
174. Oudard S, Levalois C, Andrieu JM, et al. (2002). Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res 22:121-128.
175. Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B. (2005). Tyrosine kinase inhibitor resistance in cancer: Role of ABC multidrug transporters. Drug Resist Update 8:15-26.
176. Pajic M, Murray J, Marshall GM, et al. (2011). ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript. Pharmacogenet Genomics 21:270-279.
177. Pan YZ, Zhou A, Hu Z, Yu AM. (2013). Small nucleolar RNA-derived microRNA hsa-Mir-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos 41: 1744-1751.
178. Patak P, Jin F, Schäfer ST, et al. (2011). The ATP-binding cassette transporters ABCB1 and ABCC1 are not regulated by hypoxia in immortalised human brain microvascular endothelial cells. Exp Transl Stroke Med 3:12.
179. Peng KC, Cluzeaud F, Bens M, et al. (1999). Tissue and cell distribution of the multidrug resistance-associated protein (MRP) in mouse intestine and kidney. J Histochem Cytochem 47:757-768.
180. Perdu J, Germain, DP. (2001). Identification of novel polymorphisms in the pM5 and MRP1 (ABCC1) genes at locus 16p13.1 and exclusion of both genes as responsible for pseudoxanthoma elasticum. Hum Mutat 17:74-75.
181. Petrylak DP. (2006). The treatment of hormone-refractory prostate cancer: Docetaxel and beyond. Rev Urol 8:S48-S55.
182. Plasschaert SL, de Bont ES, Boezen M, et al. (2005). Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 11: 8661-8668.
183. Porro A, Haber M, Diolaiti D, et al. (2010). Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells. J Biol Chem 285: 19532-19543.
184. Pulte D, Gondos A, Brenner H. (2009). Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood 113:1408-1411.
185. Qin L, Zheng J, Grant CE, et al. (2008). Residues responsible for the asymmetric function of the nucleotide binding domains of multidrug resistance protein 1. Biochemistry 47:13952-13965.
186. Ramaen O, Leulliot N, Sizun C, et al. (2006). Structure of the human multidrug resistance protein 1 nucleotide binding domain 1 bound to Mg2+/ATP reveals a non-productive catalytic site. J Mol Biol 359: 940-949.
187. Ramjeesingh M, Li C, Garami E, et al. (1999). Walker mutations reveal loose relationship between catalytic and channel-gating activities of purified CFTR (cystic fibrosis transmembrane conductance regulator). Biochemistry 38:1463-1468.
188. Reeves DJ, Liu CY. (2009). Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol 64:11-25.
189. Robey RW, Lin B, Qiu J, et al. (2011). Rapid detection of ABC transporter interaction: Potential utility in pharmacology. J Pharmacol Toxicol Methods 63:217-222.
190. Roelofsen H, Vos TA, Schippers IJ, et al. (1997). Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. Gastroenterology 112:511-521.
191. Rudas M, Filipits M, Taucher S, et al. (2003). Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat 81:149-157.
192. Rungsardthong K, Mares-Sámano S, Penny J. (2012). Virtual screening of ABCC1 transporter nucleotidebinding domains as a therapeutic target in multidrug resistant cancer. Bioinformation 8:907-911.
193. Saito S, Iida A, Sekine A, et al. (2002). Identification of 779 genetic variations in eight genes encoding the members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR). J Hum Genet 47:147-171.
194. Sakaeda T, Nakamura T, Okumura K. (2004). Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr Top Med Chem 4:1385-1398.
195. Sampath J, Sun D, Kidd VJ, et al. (2001). Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276:39359-39367.
196. Seeger RC, Brodeur GM, Sather H, et al. (1985). Association of multiple copies of the N-myc oncogene with rapid progression of neuroblast-omas. N Engl J Med 313:1111-1116.
197. Seiden MV, Swenerton KD, Matulonis U, et al. (2002). A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 86:302-310.
198. Semsei AF, Erdelyi DJ, Ungvari I, et al. (2012). ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lympho-blastic leukaemia. Cell Biol Int 36:79-86.
199. Shankar SM, Marina N, Hudson MM, et al. (2008). Monitoring for cardiovascular disease in survivors of childhood cancer: Report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 121:e387-e396.
200. Shiau YC, Tsai SC, Wang JJ, et al. (2001). To predict chemotherapy response using technetium-99m tetrofosmin and compare with p-glycoprotein and multidrug resistance related protein-1 expression in patients with untreated small cell lung cancer. Cancer Lett 169: 181-188.
201. Schaub TP, Kartenbeck J, König J, et al. (1999). Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 10: 1159-1169.
202. Schwab M. (2004). MYCN in neuronal tumours. Cancer Lett 204: 179-187.
203. Siegel R, Naishadham D, Jemal A. (2013). Cancer statistics, 2013. CA Cancer J Clin 63:11-30.
204. Sissung TM, Baum CE, Kirkland CT, et al. (2010). Pharmacogenetics of membrane transporters: An update on current approaches. Mol Biotechnol 44:152-167.
205. Smith PC, Karpowich N, Millen L, et al. (2002). ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer. Mol Cell 10:139-149.
206. Slapak CA, Fracasso PM, Martell RL, et al. (1994). Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleu-kemia cells. Cancer Res 54:5607-5613.
207. Spudich A, Kilic E, Xing H, et al. (2006). Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischaemia. Nat Neurosci 9:487-488.
208. Srimunta U, Sawanyawisuth K, Kraiklang R, et al. (2012). High expression of ABCC1 indicates poor prognosis in intrahepatic cholangiocarcinoma. Asian Pac J Cancer Prev 13:125-130.
209. Stolarczyk EI, Reiling CJ, Pickin KA, et al. (2012). Casein kinase 2a regulates multidrug resistance-associated protein 1 function via phosphorylation of Thr249. Mol Pharmacol 82:488-499.
210. St. Pierre MV, Serrano MA, Macias RI, et al. (2000). Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 279: R1495-R1503.
211. Sugiyama D, Kusuhara H, Lee YJ, Sugiyama Y. (2003). Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-D-17beta-glucuronide (E217betaG) across the blood-brain barrier. Pharm Res 20:1394-1400.
212. Sullivan GF, Amenta PS, Villanueva JD, et al. (1998). The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 4:1393-1403.
213. Sullivan GF, Yang JM, Vassil A, et al. (2000). Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest 105:1261-1267.
214. Sun Z, Chen J, Aakre J, et al. (2010). Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. Ann Oncol 21:2011-2016.
215. Suzuki H, Sugiyama Y. (1998). Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2. Semin Liver Dis 18:359-376.
216. Szakács G, Annereau JP, Lababidi S, et al. (2004). Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell 6:129-137.
217. Szakács G, Ozvegy C, Bakos E, et al. (2000). Transitionstate formation in ATPase-negative mutants of human MDR1 protein. Biochem Biophys Res Commun 276:1314-1319.
218. Szakács G, Paterson JK, Ludwig JA, et al. (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234.
219. Tada Y, Wada M, Migita T, et al. (2002). Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer 98: 630-635.
220. Tanaka M, Okazaki T, Suzuki H, et al. (2011). Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. Cancer 117:744-751.
221. Tannock IF, de Wit R, Berry WR, et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512.
222. Thiebaut F, Tsuruo T, Hamada H, et al. (1987). Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
223. Thomas F, Motsinger-Reif AA, Hoskins JM, et al. (2011). Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer 105:1654-1662.
224. Thomas H, Coley HM. (2003). Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10:159-165.
225. Toyoda Y, Hagiya Y, Adachi T, et al. (2008). MRP class of human ATP binding cassette (ABC) transporters: Historical background and new research directions. Xenobiotica 38:833-862.
226. Tribull TE, Bruner RH, Bain LJ. (2003). The multidrug resistance associated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury. Toxicol Lett 142:61-70.
227. Triller N, Korosec P, Kern I, et al. (2006). Multidrug resistance in small cell lung cancer: Expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 54:235-240.
228. Trnková Z, Bedrĺiková R, Marková J, et al. (2007). Semiquantitative RT-PCR evaluation of the MDR1 gene expression in patients with acute myeloid leukemia. Neoplasma 54:383-390.
229. Urquhart BL, Kim RB. (2009). Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 65:1063-1070.
230. Ushijima R, Takayama K, Izumi M, et al. (2007). Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer. Anticancer Res 27: 4351-4358.
231. van den Heuvel-Eibrink MM, Sonneveld P, Pieters R. (2000). The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 38: 94-110.
232. van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, et al. (2007). CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol 86:329-337.
233. Vassilev LT. (2007). MDM2 inhibitors for cancer therapy. Trends Mol Med 13:23-31.
234. Viale PH, Yamamoto DS. (2008). Cardiovascular toxicity associated with cancer treatment. Clin J Oncol Nurs 12:627-638.
235. Vogiatzi P, Cassone M, Claudio L, Claudio PP. (2009). Targeted therapy for advanced prostate cancer: Looking through new lenses. Drug News Perspect 22:593-601.
236. Vulsteke C, Lambrechts D, Dieudonné A, et al. (2013). Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol 24:1513-1525.
237. Walsh N, Kennedy S, Larkin AM, et al. (2010). Membrane transport proteins in human melanoma: Associations with tumour aggressiveness and metastasis. Br J Cancer 102:1157-1162.
238. Walsh N, Larkin A, Kennedy S, et al. (2009). Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol 9:6.
239. Walter RB, Raden BW, Hong TC, et al. (2003). Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 102:1466-1473.
240. Wang L, Giannoudis A, Lane S, et al. (2008). Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83:258-264.
241. Wang Z, Sew PH, Ambrose H, et al. (2006). Nucleotide sequence analyses of the MRP1 gene in four populations suggest negative selection on its coding region. BMC Genomics 7:111.
242. Wang Z, Wang B, Tang K, et al. (2005). A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection. Hum Mol Genet 14:2075-2087.
243. Warren RB, Smith RL, Campalani E, et al. (2008). Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 128:1925-1929.
244. Williams GC, Liu A, Knipp G, Sinko PJ. (2002). Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother 46:3456-3462.
245. Wojnowski L, Kulle B, Schirmer M, et al. (2005). NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112:3754-3762.
246. Wright SR, Boag AH, Valdimarsson G, et al. (1998). Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. Clin Cancer Res 4:2279-2289.
247. Xia CQ, Smith PG. (2012). Drug efflux transporters and multidrug resistance in acute leukemia: Therapeutic impact and novel approaches to mediation. Mol Pharmacol 82:1008-1021.
248. Yamada A, Ishikawa T, Ota I, et al. (2013). High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res Treat 137:773-782.
249. Yamauchi T, Matsuda Y, Tasaki T, et al. (2012). Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells. Cancer Sci 103:1722-1729.
250. Yanagisawa T, Newman A, Coley H, et al. (1999). BIRICODAR (VX-710; Incel): An effective chemosensitizer in neuroblastoma. Br J Cancer 80:1190-1196.
251. Yeh JJ, Hsu NY, Hsu WH, et al. (2005). Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung 183:177-183.
252. Yin J, Zhang J. (2011). Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: From discovery to clinical application. Zhong Nan Da Xue Xue Bao Yi Xue Ban 36:927-938.
253. Yin JY, Huang Q, Yang Y, et al. (2009). Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics 19: 206-216.
254. Yin JY, Han LF, Huang Q, et al. (2011). ABCC1 polymorphism Arg723Gln (2168G4A) is associated with lung cancer susceptibility in a Chinese population. Clin Exp Pharmacol Physiol 38:632-637.
255. Yokoi T, Nakajima M. (2013). microRNAs as mediators of drug toxicity. Annu Rev Pharmacol Toxicol 53:377-400.
256. Young LC, Campling BG, Voskoglou-Nomikos T, et al. (1999). Expression of multidrug resistance protein-related genes in lung cancer: Correlation with drug response. Clin Cancer Res 5:673-680.
257. Yu AM. (2009). Role of microRNAs in the regulation of drug metabolism and disposition. Expert Opin Drug Metab Toxicol 5: 1513-1528.
258. Zajchowski DA, Karlan BY, Shawver LK. (2012). Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther 11:492-502.
259. Zalcberg J, Hu XF, Slater A, et al. (2000). MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer Prostatic Dis 3:66-75.
260. Zaman GJ, Flens MJ, van Leusden MR, et al. (1994). The human multidrug resistanceassociated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91:8822-8826.
261. Zaman GJ, Lankelma J, van Tellingen O, et al. (1995). Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 92:7690-7694.
262. Zhang W, Shannon WD, Duncan J, et al. (2006). Expression of drug pathway proteins is independent of tumour type. J Pathol 209: 213-219.
263. Zhang Y, Schuetz JD, Elmquist WF, Miller DW. (2004). Plasma membrane localization of multidrug resistance-associated protein homologues in brain capillary endothelial cells. J Pharmacol Exp Ther 311:449-455.
264. Zhao J, Yu BY, Wang DY, Yang JE. (2010). Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma. World J Gastroenterol 16:6104-6110.
265. Zimmermann C, Gutmann H, Hruz P, et al. (2005). Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos 33:219-224.